Short description
Lixte Biotechnology is a clinical-stage pharmaceutical company that focuses on discovering drugs for effective cancer treatments.
Description
Lixte Biotechnology is a clinical-stage public pharmaceutical company that focuses on discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.
Last funding
Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
East Setauket, New York, United States, North America
Founded on
January 1, 2004
Exited on
June 5, 2009
Went public on
June 5, 2009
Stock symbol
LIXT
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$7890 - 12340
Sign in for full access
Founders
John S. Kovach